Shire, 2 generics-makers settle litigation tied to Intuniv

04/26/2013 | Reuters

Shire settled all litigation with Watson Pharma and Actavis regarding its attention-deficit/hyperactivity disorder treatment Intuniv. Under the settlement, Actavis can produce and market its generic copy of the drug in the U.S. starting Dec. 1, 2014, while Watson could follow with its version 181 days after the release of Actavis' version.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR